Stock research
CRVO CervoMed Inc.
Healthcare • Biotechnology
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally...…
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
5Y change
-93.31%
Range high
$45.75
Congress · 90d
0
Insiders · 90d
0
Public signal layer
Who is disclosing activity in CRVO?
Price
Showing 5Y history. Source: FMP historical price full.
- Prev Close
- $2.80
- Day High
- $2.87
- Day Low
- $2.73
- 52w High
- $11.25
- 52w Low
- $2.13
- Volume
- 249,393
- Avg Volume
- Beta
- -4.421
* TTM/most recent where available
Company
- Ticker
- CRVO
- Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- CEO
- John J. Alam
- Employees
- 15
- Website
- www.cervomed.com
Key Metrics
- Market Cap
- 25.6M
- P/E
- P/B
- P/S
- EV/EBITDA
- ROE
- Net Margin
- Div Yield
- FCF/Share
* TTM/most recent where available
DCF Valuation
Standard DCF
Levered DCF
Market Price
DCF vs Price (30D window)
Price uses last 30 days; DCF line holds latest value across the window.DCF line = solid green (latest value repeated across window), Price = dashed blue (daily closes).